Diabetes Research and Clinical Practice · 2021 · 23 citations · 20 references
MedicineEndocrinologyPharmacologyClinical PharmacologyDiabetologyDiabetes MellitusDiabetes PharmacotherapyGlucagon-like Peptide-1 Receptor AgonistsGlycemic ControlInsulin TherapySodium-glucose Cotransporter 2 InhibitorsAcute Adverse EventsGlucagon Receptor AgonistsGlucagon-like Peptide 1 Receptor AgonismSerious Adverse EventsSodium-glucose CotransportSodium-glucose Cotransporter 2 InhibitionType 2 Diabetes Mellitus TreatmentType 2 Diabetes Treatment
20
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6.3K citations · Full text
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg Jardine, Bruce Neal et al. · New England Journal of Medicine · 2019 · 6K citations · Full text
Medicine, Nephrology, Pharmacology +17